Risk of Myocardial Infarction in Patients with HIV Infection Exposed to Specific Individual Antiretroviral Drugs from the 3 Major Drug Classes: The Data Collection on Adverse Events of Anti‐HIV Drugs (D:A:D) Study

This publication has 13 references indexed in Scilit:

• Nevirapine Increases High-Density Lipoprotein Cholesterol Concentration by Stimulation of Apolipoprotein A-I Production
  Arteriosclerosis, Thrombosis, and Vascular Biology, 2009
• Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients
  AIDS, 2008
• No Impairment of Endothelial Function or Insulin Sensitivity with 4 Weeks of the HIV Protease Inhibitors Atazanavir or Lopinavir‐Ritonavir in Healthy Subjects without HIV Infection: A Placebo‐Controlled Trial
  Clinical Infectious Diseases, 2008
• Changes Over Time in Risk Factors for Cardiovascular Disease and Use of Lipid‐Lowering Drugs in HIV‐Infected Individuals and Impact on Myocardial Infarction
  Clinical Infectious Diseases, 2008
• Impact of steady-state lopinavir plasma levels on plasma lipids and body composition after 24 weeks of lopinavir/ritonavir-containing therapy free of thymidine analogues
  Journal of Antimicrobial Chemotherapy, 2007
• Factors Associated with the Incidence of Type 2 Diabetes Mellitus in HIV-Infected Participants in the Swiss HIV Cohort Study
  Clinical Infectious Diseases, 2007
• Metabolic Syndrome in HIV-Infected Patients from an Urban, Midwestern US Outpatient Population
  Clinical Infectious Diseases, 2007
• Nevirapine and Efavirenz Elicit Different Changes in Lipid Profiles in Antiretroviral- Therapy-Naive Patients Infected with HIV-1
  PLoS Medicine, 2004
• Cardiovascular disease risk factors in HIV patients – association with antiretroviral therapy. Results from the DAD study
  AIDS, 2003
• Continued indinavir versus switching to indinavir/ritonavir in HIV-infected patients with suppressed viral load
  AIDS, 2003